Dementia with Lewy bodies: Therapeutic opportunities and pitfalls

Consultant Pharmacist

Volumn 21, Issue 7, 2006, Pages 563-575

  Henriksen, Anne Lenora ^a,h   St Dennis, Clarke ^b,c   Setter, Stephen M ^b,d   Tran, John T ^a,e,f,g  

^a Department of Pharmacy   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Elder Services   (United States)

^e Spokane Mental Health   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g WASHINGTON STATE UNIVERSITY   (United States)

^h NONE   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Lewy bodies; Neuroleptic sensitivity; Parkinson's disease

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; GALANTAMINE; HALOPERIDOL; LEVODOPA; LOXAPINE; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TACRINE; THIORIDAZINE; ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; AMNESIA; ANOREXIA; BEHAVIOR DISORDER; BRUXISM; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; DATA BASE; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIAGNOSTIC ERROR; DIARRHEA; DISEASE ASSOCIATION; DROWSINESS; DRUG DOSE REDUCTION; DYSKINESIA; DYSPEPSIA; FALLING; FATIGUE; HALLUCINATION; HUMAN; INSOMNIA; LEWY BODY; MORTALITY; MULTIINFARCT DEMENTIA; MUSCLE RIGIDITY; MUTISM; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PSYCHOSOMATIC DISORDER; REM SLEEP DEPRIVATION; REVIEW; SIDE EFFECT; SOMNOLENCE; SYNCOPE; THROMBOCYTOPENIA; TREMOR; UNCONSCIOUSNESS; VERTIGO; VISUAL HALLUCINATION; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; DIFFUSE LEWY BODY DISEASE; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; HUMANS; LEWY BODY DISEASE; MEMANTINE; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 85047277927     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2006.563     Document Type: Review

References (77)

1. McKeith I, Galasko D, Kosoka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-24.
2. McKeith I, Perry E, Perry R. Report of the Second Dementia with Lewy Body International Workshop: diagnosis and treatment. Neurology 1999;53:902-5.
3. Mosimann UP, McKeith IG. Dementia with Lewy bodies-diagnosis and treatment. Swiss Med Wkly 2003;133:131-42.
4. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-44.
5. Lennox G, Lowe J, Morrell K et al. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71.
6. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 1995;116:1447-59.
7. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
8. Duda J. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;17(suppl 1):3-14.
9. Mori F, Piao Y-S, Hayashi S et al. α-Synuclein accumulates in purkinje cells in Lewy body disease but not in multiple system atrophy. J Neuropathol Exp Neurology 2003;62:812-9.
10. Braak H, Sandmann-Keil D, Gai W et al. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry. Neurosci Lett 1999;265:67-9.
11. Hansen LA, Masliah E, Galasko D et al. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-54.
12. Hurtig HI, Trojanowski JQ, Galvin J et al. α-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-21.
13. Barker W, Luis C, Kashuba A et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida brain bank. Alzheimer Dis Assoc Disord 2002;16:203-12.
14. Holmes C, Cairns N, Lantos P et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45-50.
15. 125I]-A-85380. Neuropsychopharm 2004;29:108-16.
16. Tiraboschi P, Hansen L, Alford M et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002;59:946-51.
17. Lippa CF, Smith TW, Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm 1999;106:525-35.
18. Ballard C, Piggott M, Johnson M et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-76.
19. Shiozaki K, Iseki E, Hino H et al. Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study. J Neurol Sci 2001;193:23-8.
20. Perry RH, Irving D, Blessed G et al. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body-dementia in the elderly. J Neurol Sci 1990;95:119-39.
21. Piggott MA, Marshall EF, Thomas N et al. Striatal dopaminergic markers in dementia with Lewy bodies. Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-68.
22. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998;351:1032.
23. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305:673-8.
24. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1993;5:206-8.
25. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998;10:227-9.
26. Sadek J, Rockwood K. Coma with accidental single close of an atypical neuroleptic in a patient with Lewy body dementia. Am J Geriatr Psychiatry 2003;11:112-3.
27. Morikawa M, Kishimoto T. Probable dementia with Lewy bodies and risperidone-induced delirium. Can J Psychiatry 2002;47:976.
28. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995;346:699.
29. Sechi G, Agnetti V, Masuri R et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:1043-51.
30. Shiwach RS, Woods S. Risperidol and withdrawal bruxism in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:65-6.
31. Kato K, Wada T, Kawakatsu S, Otani K. Improvement of both psychotic symptoms and parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:201-3.
32. Allen RL, Walker Z, D'Ath PJ, Katona CL. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995;34e:185.
33. Hussain MF, Hussain S. Response of a patient with Lewy-body dementia to risperidone. Adv Ther 1998;15:194-6.
34. Lee H, Cooney JM, Lawlor BA. The use of risperidone, an atypical neuroleptic, in Lewy body disease. Int J Geriatr Psychiatry 1994;9:415-7.
35. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Discord 2002;13:67-73.
36. Clark WS, Street JS, Sanger TM, Breier A, Cummings JL. Reduction of psychotic symptoms bv olanzapine in patients with possible Lewy body dementia. Schizophr Res 2001;49:222.
37. Walker Z, Grace J, Overshot R et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999;14:459-66.
38. Placines B, Geny C, Albert D, Revel V, de la Fourniere F.The olanzapine-rivastigmine association in dementia with Lewy body disease: a case report. Poster: Center de Long Séjour, rue du colonel Betboy, Pontacq, France.
39. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003;24:549-53.
40. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-5.
41. Baskys A, Zhong X. Quetiapine in the treatment of psychosis associated with Lewy body dementia. Ann Neurol 2002;52(suppl):S32.
42. Baskys A, Davis P. Atypical antipsychotic quetiapine in the treatment of psychosis associated with Lewy body dementia. Schizophrenia Res 2003; 15:272-3.
43. Menza MA, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999;11:141-4.
44. Terao, T, Shimomura T, Izumi Y et al. Two case studies of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies. J Clin Psychiatry 2003;64:1520-1.
45. Levy R, Eagger S, Griffiths S et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994;343:176.
46. Witjeratne C, Bandyopadhgag D, Howard R. Failure of tacrine treatment in a case of cortical Lewy body dementia (letter). Int J Geriatr Psychiatry 1995;10:808.
47. Lebert F, Pasquier F, Souliez L, Petit H. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516-9.
48. Querfurth HW, Allam GJ, Geffroy MA, Schiff HB, Kaplan RF. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Discord 2000;11:314-21.
49. Aricept (package literature). Pfizer Pharmaceuticals, Inc.; August 2003.
50. Geizer M, Ancill RJ. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998;43:421-2.
51. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewv bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229-38.
52. Kaufer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998;15:1512.
53. Aarsland D, Bronnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999;14:69-72.
54. Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother 2001;32:202-5.
55. Skjerve A, Nygaard HA. Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int J Geriatr Psychiatry 2000;15:1147-51.
56. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 2000;15:280-1.
57. Lanctot KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000;5:338-45.
58. Samuel W, Caligiuri M, Galasko D et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000;15:794-802.
59. Onofri M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2003;61:1452.
60. Rozzini L, Ghiandi D, Trabucchi M, Pradovani A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2004;63:1543-4.
61. Minett T, Thomas A, Wilkinson L et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:988-93.
62. Holm AC. Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 2004;19:215-8.
63. Dale M, Libretto S, Patterson C et al. Clinical experience of galantamine in dementia: a series of case reports. Curr Med Res Opin 2003;19:508-18.
64. Edwards K, Hershey L, Wray L et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 1 2-week interim analysis. Dement Geriatr Cog Disord 2004;17(suppl 1):S40-S48.
65. Kaufer DI. A case study in the treatment of dementia with Lewy bodies. Acta Psychiatrica Scandinavica 2004;110:72.
66. Bhanji NH, Gauthier S. Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2005;17:552-5.
67. Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatrie symptoms, and sleep. Int Psychogeriatr 2001;13:277-88.
68. McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
69. Wesnes KA, McKeith IG, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerized assessment system. Dement Geriatr Cog Disord 2002;13:183-92.
70. McKeith IG, Grace JB, Walker Z et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000;15:387-92.
71. Del Ser T, McKeith I, Anand R et al. Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;14:1034-45.
72. Grace J, Daniel S, Stevens T et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199-205.
73. Wesnes KA, McKeith IG, Ferrara R et al. Predicting the response to rivastigmine in dementia with Lewy bodies: the role of hallucinations. J Psychopharmacol 2002;16(3, suppl):A30.
74. Menendez-Gonzalez M, Calataayud MT, Blazquez-Menes B. Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis 2005;8:289-91.
75. Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine with dementia with Lewy bodies. J Alzheimers Dis 2005;7:285-89.
76. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005;65:481-2.
77. Diagnostic and statistical manual of mental disorders, fourth edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.